Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

Date Set for Arbitration Trial Between CEL-SCI and Clinical Research Organization inVentiv

Business Wire January 6, 2015

CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase III Head and Neck Cancer Trial

Business Wire January 5, 2015

CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments

Business Wire December 23, 2014

CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites

Business Wire December 8, 2014

CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold over Same Prior Year Period

Business Wire December 2, 2014

CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial

Business Wire November 3, 2014

CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million

Business Wire October 24, 2014

CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering

Business Wire October 21, 2014

CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants

Business Wire October 21, 2014

CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants

Business Wire October 20, 2014

CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial

Business Wire October 3, 2014

Coverage Initiation Report Focuses on CEL-SCI Corporation

Marketwired October 1, 2014

CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients

Business Wire September 29, 2014

Valuation Analysis for CEL-SCI

Accesswire September 11, 2014

University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial

Business Wire September 10, 2014

CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial

Business Wire September 3, 2014

CEL-SCI Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec in Canada

Business Wire August 19, 2014

Potential Payoffs Spur Big Board Biotech Action

Accesswire August 12, 2014

CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results

Business Wire August 8, 2014

Small companies lead the I-O class of Cancer Therapies

Accesswire August 8, 2014